Chiesi Farmaceutici SpA has described amido cyclopropyl derivatives acting as lysophospholipid LPA1 receptor (LPAR1; EDG2) antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Sarcoidosis is a multisystem disorder characterized by the formation of granulomatous inflammatory nodules mainly located in the lungs, lymphatic system, skin and eyes. In patients with pulmonary involvement, targeting IFN-γ has proven ineffective. Researchers from Baylor College of Medicine and collaborators reported on the use of nonreceptor tyrosine phosphatase Src homolog-2 domain-containing phosphatase 2 (SHP2) inhibition as a potential strategy to treat sarcoidosis-like diseases.
Japan Tobacco Inc. has divulged indazole compounds acting as hematopoietic prostaglandin D synthase (HPGDS) inhibitors reported to be useful for the treatment of chronic obstructive pulmonary disease, Duchenne muscular dystrophy, peripheral arterial disease, allergic rhinitis, sarcopenia and allergic asthma.
Transforming growth factor β1 (TGF-β1) is a key mediator of the fibrotic response, and its dysregulation drives the formation of the fibrotic niche, which impairs the capacity of tissue repair, regeneration and homeostasis.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged new soluble guanylate cyclase (sGC) activators reported to be useful for the treatment of chronic obstructive pulmonary disease, fibrosis, psoriasis, erectile dysfunction, multiple sclerosis, heart failure, overactive bladder and neuropathic pain, among others.
Alveogene Ltd. has launched with a focus on inhaled gene therapies for respiratory disorders. The company has been created by Oxford Science Enterprises, Harrington Discovery Institute at University Hospitals, and Old College Capital in partnership with six scientists from the UK Respiratory Gene Therapy Consortium (GTC).
At the recent ERS meeting, researchers from Hilung Inc. and Ube Corp. presented preclinical data for the novel lysophospholipid LPA1 receptor antagonist, HL-001, being developed for the treatment of idiopathic pulmonary fibrosis (IPF).
Senescence of lung epithelial tissue translates into fibrinolysis reduction and loss of tissue repair, both drivers of pulmonary fibrotic diseases. Researchers from Tokushima University reported on the effect of ARV-825, a BRD4 degrader, as an antifibrotic agent in lung fibrosis.
Vertex Pharmaceuticals Inc. has divulged cystic fibrosis transmembrane conductance regulator (CFTR) modulators reported to be useful for the treatment of cystic fibrosis.
Researchers from Genentech Inc. presented preclinical data for the novel transient receptor potential ankyrin 1 (TRPA1) antagonist GDC-6599, currently in phase II development for respiratory indications.
RSS
